These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 23629686)

  • 1. Synthetic sickness or lethality points at candidate combination therapy targets in glioblastoma.
    Szczurek E; Misra N; Vingron M
    Int J Cancer; 2013 Nov; 133(9):2123-32. PubMed ID: 23629686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
    Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE
    Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition.
    Shen Y; Li J; Nitta M; Futalan D; Steed T; Treiber JM; Taich Z; Stevens D; Wykosky J; Chen HZ; Carter BS; Becher OJ; Kennedy R; Esashi F; Sarkaria JN; Furnari FB; Cavenee WK; Desai A; Chen CC
    Oncotarget; 2015 May; 6(14):11751-67. PubMed ID: 26059434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
    Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
    Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer: mixing cocktails.
    Sawyers CL
    Nature; 2007 Oct; 449(7165):993-6. PubMed ID: 17960228
    [No Abstract]   [Full Text] [Related]  

  • 6. Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration.
    Ruano Y; Ribalta T; de Lope AR; Campos-Martín Y; Fiaño C; Pérez-Magán E; Hernández-Moneo JL; Mollejo M; Meléndez B
    Am J Clin Pathol; 2009 Feb; 131(2):257-63. PubMed ID: 19141386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of Polo-like kinase 1 induces cellular senescence in human primary cells through a p53-dependent pathway.
    Kim HJ; Cho JH; Kim JR
    J Gerontol A Biol Sci Med Sci; 2013 Oct; 68(10):1145-56. PubMed ID: 23525475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polo-like kinases in AML.
    Berg T; Bug G; Ottmann OG; Strebhardt K
    Expert Opin Investig Drugs; 2012 Aug; 21(8):1069-74. PubMed ID: 22667760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IndividualizedPath: identifying genetic alterations contributing to the dysfunctional pathways in glioblastoma individuals.
    Ping Y; Zhang H; Deng Y; Wang L; Zhao H; Pang L; Fan H; Xu C; Li F; Zhang Y; Gong Y; Xiao Y; Li X
    Mol Biosyst; 2014 Aug; 10(8):2031-42. PubMed ID: 24911613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation.
    Younes MN; Yigitbasi OG; Park YW; Kim SJ; Jasser SA; Hawthorne VS; Yazici YD; Mandal M; Bekele BN; Bucana CD; Fidler IJ; Myers JN
    Cancer Res; 2005 Jun; 65(11):4716-27. PubMed ID: 15930290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor and AKT1 gene copy numbers by multi-gene fluorescence in situ hybridization impact on prognosis in breast cancer.
    Li J; Su W; Zhang S; Hu Y; Liu J; Zhang X; Bai J; Yuan W; Hu L; Cheng T; Zetterberg A; Lei Z; Zhang J
    Cancer Sci; 2015 May; 106(5):642-9. PubMed ID: 25702787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
    Lin YC; Sun SH; Wang FF
    Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of cytoplasmic-domain substituted epidermal growth factor receptor inhibits tumorigenicity of EGFR-overexpressed human glioblastoma multiforme.
    Liu KJ; Chen CT; Hu WS; Hung YM; Hsu CY; Chuang BF; Juang SH
    Int J Oncol; 2004 Mar; 24(3):581-90. PubMed ID: 14767543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity to
    Lee E; Pain M; Wang H; Herman JA; Toledo CM; DeLuca JG; Yong RL; Paddison P; Zhu J
    Cancer Res; 2017 Oct; 77(20):5518-5529. PubMed ID: 28855212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer.
    Maire V; Némati F; Richardson M; Vincent-Salomon A; Tesson B; Rigaill G; Gravier E; Marty-Prouvost B; De Koning L; Lang G; Gentien D; Dumont A; Barillot E; Marangoni E; Decaudin D; Roman-Roman S; Pierré A; Cruzalegui F; Depil S; Tucker GC; Dubois T
    Cancer Res; 2013 Jan; 73(2):813-23. PubMed ID: 23144294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B; Chang CM; Yuan M; McKenna WG; Shu HK
    Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner.
    Chakravarti A; Chakladar A; Delaney MA; Latham DE; Loeffler JS
    Cancer Res; 2002 Aug; 62(15):4307-15. PubMed ID: 12154034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ranking novel cancer driving synthetic lethal gene pairs using TCGA data.
    Ye H; Zhang X; Chen Y; Liu Q; Wei J
    Oncotarget; 2016 Aug; 7(34):55352-55367. PubMed ID: 27438146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma.
    Michiue H; Eguchi A; Scadeng M; Dowdy SF
    Cancer Biol Ther; 2009 Dec; 8(23):2306-13. PubMed ID: 19901546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.